Startups
Ilios Therapeutics
Ilios Therapeutics develops multifunctional small molecules for neurodegenerative diseases. Its chemistry platform combines bioactive components to address protein mislocalization, oxidative stress and neuroinflammation, with a lead research program in ALS and frontotemporal dementia. It operates at Harvard's Pagliuca Life Lab in Boston.
Team
Amy ElderHead of Drug Discovery |
 Barbara TateScientific Advisor, Neuroscience |
Brad DickersonScientific Advisor, Frontotemporal Disorders |
Christiano AlvesScientific Advisor, Neurobiology |
Elias PavlopoulosScientific Advisor, Neuroscience and Neurodegeneration |
Emanuele BurattiScientific Advisor, TDP-43, ALS and FTD Preclinical |
Fares NigimCo-Founder and Scientific Advisor, Translational Neuroscience |
John LandersScientific Advisor, ALS Genetics and Preclinical Sciences |
Jonathan LevensonManagement Team Member, Translational Biology |
Kelley C. LarsonHead of Neuropharmacology |
Lawrence SteinmanScientific Advisor, Neurology |
Lisa PaborskySenior Strategic Advisor |
 Luca GianiCo-Founder and CEO |
Rosana KapellerBlavatnik Fellowship Advisor |
Sabrina PaganoniScientific Advisor, ALS Clinical Sciences |
Stephen HaggartyScientific Advisor, Chemical Neurobiology |
Zaven KaprielianChief Scientific Officer |